S'abonner

Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: A pilot study - 24/04/13

Doi : 10.1016/j.jaad.2008.05.032 
Matthew Delfino, MBA a, Elizabeth W. Holt, MPH b, Charles R. Taylor, MD c, Eve Wittenberg, PhD d, Abrar A. Qureshi, MD, MPH a,
a Department of Dermatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 
b Department of Epidemiology, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana 
c Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 
d Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts 

Reprint requests: Abrar A. Qureshi, MD, MPH, Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, 45 Francis St, 221L, Boston, MA 02115.

Abstract

Background

Psoriasis is a chronic skin condition that has a major impact on health-related quality of life (QOL). We evaluated health-related QOL via willingness to pay and a ranking task for 8 domains of health relevant to psoriasis: intimacy, physical comfort, self-care, ability to work or volunteer, ability to concentrate, emotional health, social comfort, and ability to sleep.

Objective

The goals of the study were to pilot test a new method to measure QOL impact in psoriasis and identify the areas of life most affected by psoriasis.

Methods

Forty participants with a history of psoriasis were interviewed in a face-to-face format. First, participants were asked to rank the 8 domains of health we were investigating. Second, patients were asked how much money they would be willing to pay for a hypothetical cure for each domain of health. Responses in US dollars were interpreted as strength of preference rather than absolute monetary values.

Results

About half of the patients in the sample (48%) were female, 60% had a college degree or further education, and 38% had an income level over $45,000/y. Physical comfort, social comfort, and emotional health were highly ranked by more than 75% of respondents. Ability to concentrate was least likely to be affected by psoriasis with just a quarter (25.7%) of respondents ranking this domain as important. The median amount patients were willing to pay for a hypothetical cure of psoriasis specific to a particular domain was highest for physical comfort ($2000, 25th quartile = $500, 75th quartile = $5500) and emotional health ($2000, 25th quartile = $250, 75th quartile = $5000), and lowest for ability to sleep ($625, 25th quartile = $50, 75th quartile = $5000).

Limitations

The sample size is modest for this pilot study. Willingness to pay as a method of eliciting stated preferences for qualitative aspects of health may be influenced by individual perception of money.

Conclusions

This study successfully pilot tested a willingness-to-pay method and a ranking task to measure the relative severity of 8 domains of health-related QOL and found that physical comfort, social comfort, and emotional health were the domains of health most affected by psoriasis.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : BSA, HRQOL, PRO, QOL, WTP


Plan


 Supported by grant number 5 K02 HS014010 from the Agency for Healthcare Research and Quality (Dr Wittenberg).
 Disclosure: Dr Qureshi is a consultant and has spoken for Abbott, Amgen, and Genentech and has a limited consulting relationship with Centocor. Mr Delfino, Ms Holt, and Drs Taylor and Wittenberg have no conflicts of interest to declare.


© 2008  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 59 - N° 3

P. 439-447 - septembre 2008 Retour au numéro
Article précédent Article précédent
  • Determinants of marginal traction alopecia in African girls and women
  • Nonhlanhla P. Khumalo, Susan Jessop, Freedom Gumedze, Rodney Ehrlich
| Article suivant Article suivant
  • Clobetasol propionate emulsion formulation foam 0.05%: Review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents
  • Alexa Boer Kimball, Michael H. Gold, Beth Zib, Mark W. Davis, Clobetasol Propionate Emulsion Formulation Foam Phase III Clinical Study Group ∗

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.